

## Appendix 3Y

### Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	Medibio Limited
<b>ABN</b>	58 008 130 336

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Claude Solitario
<b>Date of last notice</b>	18 June 2019

#### **Part 1 - Change of director's relevant interests in securities**

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct and Indirect
<b>Nature of indirect interest (including registered holder)</b> Note: Provide details of the circumstances giving rise to the relevant interest.	Mr Claude Solitario <Solitario Family A/C> (Director)
<b>Date of change</b>	29 August 2019
<b>No. of securities held prior to change</b>	<b><u>Direct</u></b> 3,000 Fully Paid Ordinary Shares  <b><u>Indirect</u></b> 11,476,536 Fully Paid Ordinary Shares; 15,166,520 Convertible Notes maturing 18 June 2020; and 3,000,000 Unlisted Options exercisable at \$0.014 expiring 13 June 2023.

---

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

<b>Class</b>	<ol style="list-style-type: none"> <li>1. Convertible Notes;</li> <li>2. Fully Paid Ordinary Shares;</li> <li>3. Quoted Options exercisable at \$0.03 per option and expiring on 1 December 2021; and</li> <li>4. Unlisted Options exercisable at \$0.015 per option expiring 19 August 2024.</li> </ol>
<b>Number acquired</b>	<ol style="list-style-type: none"> <li>2. 30,333,040 Fully Paid Ordinary Shares</li> <li>3. 30,333,040 Quoted Options</li> <li>4. 4,000,000 Unlisted Options</li> </ol>
<b>Number disposed</b>	<ol style="list-style-type: none"> <li>1. 15,166,520 Convertible Notes</li> </ol>
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	<ol style="list-style-type: none"> <li>1. Nil</li> <li>2. Nil</li> <li>3. Nil</li> <li>4. Nil</li> </ol>
<b>No. of securities held after change</b>	<p><b><u>Direct</u></b>            3,000 Fully Paid Ordinary shares</p> <p><b><u>Indirect</u></b>            41,809,576 Fully Paid Ordinary Shares;            30,333,040 Quoted Options exercisable at \$0.03 each and expiring 1 December 2021;            3,000,000 Unlisted Options exercisable at \$0.014 expiring 13 June 2023; and            4,000,000 Unlisted Options exercisable at \$0.015 per option expiring 19 August 2024.</p>
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	<ol style="list-style-type: none"> <li>1. Convertible Notes conversion as announced on 10 July 2019;</li> <li>2. Fully Paid Ordinary Shares issued upon Conversion of Convertible Notes as announced 10 July 2019;</li> <li>3. Quoted options issued upon conversion of Convertible Notes as approved by shareholders on 19 August 2019; and</li> <li>4. Fully Paid Ordinary Shares issued to a related party of Mr Solitario as approved by shareholders on 19 August 2019.</li> </ol>

+ See chapter 19 for defined terms.

**Part 2 – Change of director's interests in contracts**

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	N/A
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	N/A
<b>Interest after change</b>	N/A

**Part 3 – <sup>+</sup>Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

---

<sup>+</sup> See chapter 19 for defined terms.

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	Medibio Limited
<b>ABN</b>	58 008 130 336

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	David Kaysen
<b>Date of last notice</b>	8 November 2018

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (j) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct
<b>Nature of indirect interest (including registered holder)</b> Note: Provide details of the circumstances giving rise to the relevant interest.	-
<b>Date of change</b>	29 August 2019
<b>No. of securities held prior to change</b>	Nil
<b>Class</b>	Unlisted Options
<b>Number acquired</b>	15,000,000 Unlisted options exercisable at \$0.015 expiring 19 August 2024
<b>Number disposed</b>	Nil
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	Nil
<b>No. of securities held after change</b>	15,000,000 Unlisted options exercisable at \$0.015 expiring 19 August 2024

+ See chapter 19 for defined terms.

## Appendix 3Y

### Change of Director's Interest Notice

---

<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issue of Unlisted Options as approved by shareholders on 19 August 2019
---	---

#### Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	N/A
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	N/A
<b>Interest after change</b>	N/A

#### Part 3 – <sup>+</sup>Closed period

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

---

<sup>+</sup> See chapter 19 for defined terms.

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	Medibio Limited
<b>ABN</b>	58 008 130 336

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Melanie Leydin
<b>Date of last notice</b>	22 February 2019

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (j) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Indirect
<b>Nature of indirect interest (including registered holder)</b> Note: Provide details of the circumstances giving rise to the relevant interest.	TMENA Pty Ltd <Combivan Pty Ltd Account> (Director)
<b>Date of change</b>	29 August 2019
<b>No. of securities held prior to change</b>	Nil
<b>Class</b>	Unlisted Options
<b>Number acquired</b>	2,600,000 Unlisted options exercisable at \$0.02 expiring on 19 August 2023
<b>Number disposed</b>	Nil
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	Nil
<b>No. of securities held after change</b>	2,600,000 Unlisted options exercisable at \$0.02 expiring on 19 August 2023

+ See chapter 19 for defined terms.

## Appendix 3Y Change of Director's Interest Notice

---

<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issue of Unlisted Options as approved by shareholders on 19 August 2019
---	---

### Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	N/A
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	N/A
<b>Interest after change</b>	N/A

### Part 3 – <sup>+</sup>Closed period

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

---

<sup>+</sup> See chapter 19 for defined terms.